NICE final appraisal recommends funding Iluvien for pseudophakic DME patients

The United Kingdom’s National Institute for Health and Care Excellence, or NICE, has issued a final appraisal determination calling for funding of Iluvien for the treatment of pseudophakic eyes in patients with chronic diabetic macular edema considered insufficiently responsive to available therapies, according to a news release.The determination takes into account Alimera Sciences’ patient access scheme, which a NICE appraisal committee found in June met the necessary cost-effectiveness threshold. The final appraisal reverses NICE’s guidance from January.

Full Story →